Research Progress of PD-L1 Expression in Circulating Tumor Cells in Malignant Tumors

LI Zuxi; HUANG Xianbin; MA Yuntao; ZHAN Weipeng; HU Ming; TIAN Hongwei; YANG Jing

doi:10.3971/j.issn.1000-8578.2022.21.0648

Cancer Research on Prevention and Treatment > 2022 > 49(3): 225-229. > DOI: 10.3971/j.issn.1000-8578.2022.21.0648

LI Zuxi, HUANG Xianbin, MA Yuntao, ZHAN Weipeng, HU Ming, TIAN Hongwei, YANG Jing. Research Progress of PD-L1 Expression in Circulating Tumor Cells in Malignant Tumors[J]. Cancer Research on Prevention and Treatment, 2022, 49(3): 225-229. DOI: 10.3971/j.issn.1000-8578.2022.21.0648

Citation:

PDF (4119 KB)

Research Progress of PD-L1 Expression in Circulating Tumor Cells in Malignant Tumors

1.
The First Clinical Medical College of Gansu University of Chinese Medicine, Lanzhou 730000, China
2.
Key Laboratory of Molecular Diagnostics and Precision Medicine for Surgical Oncology in Gansu Province, Gansu Provincial Hospital, Lanzhou 730000, China

Funding:

Gansu Provincial Key Laboratory of Molecular Diagnosis and Precision Therapy of Surgical Tumors 2019GSZDSYS06

Gansu Natural Science Foundation 21JR1RA017

Internal Scientific Research Fund of Gansu Provincial People's Hospital 21GSSYB-5

More Information

Corresponding author:
YANG Jing, E-mail: 21634604@qq.com
Received Date: June 06, 2021
Revised Date: September 28, 2021
Available Online: January 12, 2024

Graphical Abstract

Abstract

Abstract

In recent years, with the in-depth study of PD-1 and PD-L1 and the development of immunotherapy, the first problem is how to screen the beneficiaries. Recent clinical studies have shown that the expression level of PD-L1 in circulating tumor cells (CTC) can be used as a potential biomarker to play a guiding role in immunotherapy of malignant tumors. This article reviews the latest clinical research progress on the expression of PD-L1 in circulating tumor cells in various solid tumors.
- Circulating tumor cell,
- Liquid biopsy,
- Prognosis judgment,
- Efficacy evaluation,
- Immunotherapy monitoring

FullText(HTML)

Competing interests: The authors declare that they have no competing interests.

References (37)

References

[1]	Bakir B, Chiarella AM, Pitarresi JR, et al. EMT, MET, Plasticity, and Tumor Metastasis[J]. Trends Cell Biol, 2020, 30(10): 764-776. doi: 10.1016/j.tcb.2020.07.003
[2]	Follain G, Herrmann D, Harlepp S, et al. Fluids and their mechanics in tumour transit: shaping metastasis[J]. Nat Rev Cancer, 2020, 20(2): 107-124. doi: 10.1038/s41568-019-0221-x
[3]	Vasseur A, Kiavue N, Bidard FC, et al. Clinical utility of circulating tumor cells: an update[J]. Mol Oncol, 2021, 15(6): 1647-1666. doi: 10.1002/1878-0261.12869
[4]	Allen TA, Asad D, Amu E, et al. Circulating tumor cells exit circulation while maintaining multicellularity, augmenting metastatic potential[J]. J Cell Sci, 2019, 132(17): jcs231563.
[5]	Xie N, Hu Z, Tian C, et al. In Vivo Detection of CTC and CTC Plakoglobin Status Helps Predict Prognosis in Patients with Metastatic Breast Cancer[J]. Pathol Oncol Res, 2020, 26(4): 2435-2442. doi: 10.1007/s12253-020-00847-7
[6]	Qi LN, Xiang BD, Wu FX, et al. Circulating Tumor Cells Undergoing EMT Provide a Metric for Diagnosis and Prognosis of Patients with Hepatocellular Carcinoma[J]. Cancer Res, 2018, 78(16): 4731-4744. doi: 10.1158/0008-5472.CAN-17-2459
[7]	Papadaki MA, Koutsopoulos AV, Tsoulfas PG, et al. Clinical Relevance of Immune Checkpoints on Circulating Tumor Cells in Breast Cancer[J]. Cancers (Basel), 2020, 12(2): 376. doi: 10.3390/cancers12020376
[8]	Jacot W, Mazel M, Mollevi C, et al. Clinical Correlations of Programmed Cell Death Ligand 1 Status in Liquid and Standard Biopsies in Breast Cancer[J]. Clin Chem, 2020, 66(8): 1093-1101. doi: 10.1093/clinchem/hvaa121
[9]	Stott SL, Hsu CH, Tsukrov DI, et al. Isolation of circulating tumor cells using a microvortex-generating herringbone-chip[J]. Proc Natl Acad Sci U S A, 2010, 107(43): 18392-18397. doi: 10.1073/pnas.1012539107
[10]	Sheng W, Ogunwobi OO, Chen T, et al. Capture, release and culture of circulating tumor cells from pancreatic cancer patients using an enhanced mixing chip[J]. Lab Chip, 2014, 14(1): 89-98. doi: 10.1039/C3LC51017D
[11]	Wang Z, Wu W, Wang Z, et al. Ex vivo expansion of circulating lung tumor cells based on one-step microfluidics-based immunomagnetic isolation[J]. Analyst, 2016, 141(12): 3621-3625. doi: 10.1039/C5AN02554K
[12]	Zhang J, Chen K, Fan ZH. Circulating Tumor Cell Isolation and Analysis[J]. Adv Clin Chem, 2016, 75: 1-31.
[13]	Wang Y, Wu J, Deng J, et al. The detection value of PD-L1 expression in biopsy specimens and surgical resection specimens in non-small cell lung cancer: a meta-analysis[J]. J Thorac Dis, 2021, 13(7): 4301-4310. doi: 10.21037/jtd-21-543
[14]	Namikawa K, Yamazaki N. Targeted Therapy and Immunotherapy for Melanoma in Japan[J]. Curr Treat Options Oncol, 2019, 20(1): 7. doi: 10.1007/s11864-019-0607-8
[15]	Judd J, Borghaei H. Combining Immunotherapy and Chemotherapy for Non-Small Cell Lung Cancer[J]. Thorac Surg Clin, 2020, 30(2): 199-206. doi: 10.1016/j.thorsurg.2020.01.006
[16]	Reck M, Rodríguez-Abreu D, Robinson AG, et al. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater[J]. J Clin Oncol, 2019, 37(7): 537-546. doi: 10.1200/JCO.18.00149
[17]	Koch C, Kuske A, Joosse SA, et al. Characterization of circulating breast cancer cells with tumorigenic and metastatic capacity[J]. EMBO Mol Med, 2020, 12(9): e11908.
[18]	Liang DH, Hall C, Lucci A. Circulating Tumor Cells in Breast Cancer[J]. Recent Results Cancer Res, 2020, 215: 127-145.
[19]	Ahn JC, Teng PC, Chen PJ, et al. Detection of Circulating Tumor Cells and Their Implications as a Biomarker for Diagnosis, Prognostication, and Therapeutic Monitoring in Hepatocellular Carcinoma[J]. Hepatology, 2021, 73(1): 422-436. doi: 10.1002/hep.31165
[20]	Yue C, Jiang Y, Li P, et al. Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy[J]. Oncoimmunology, 2018, 7(7): e1438111. doi: 10.1080/2162402X.2018.1438111
[21]	Tomita Y, Oronsky B, Abrouk N, et al. In small cell lung cancer patients treated with RRx-001, a downregulator of CD47, decreased expression of PD-L1 on circulating tumor cells significantly correlates with clinical benefit[J]. Transl Lung Cancer Res, 2021, 10(1): 274-278. doi: 10.21037/tlcr-20-359
[22]	Nicolazzo C, Raimondi C, Mancini M, et al. Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab[J]. Sci Rep, 2016, 6: 31726. doi: 10.1038/srep31726
[23]	Raimondi L, Raimondi FM, Di Benedetto L, et al. PD-L1 Expression on Circulating Tumour Cells May Be Predictive of Response to Regorafenib in Patients Diagnosed with Chemorefractory Metastatic Colorectal Cancer[J]. Int J Mol Sci, 2020, 21(18): 6907. doi: 10.3390/ijms21186907
[24]	Anantharaman A, Friedlander T, Lu D, et al. Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients[J]. BMC Cancer, 2016, 16(1): 744. doi: 10.1186/s12885-016-2758-3
[25]	Strati A, Koutsodontis G, Papaxoinis G, et al. Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma[J]. Ann Oncol, 2017, 28(8): 1923-1933. doi: 10.1093/annonc/mdx206
[26]	Cheng Y, Wang T, Lv X, et al. Detection of PD-L1 Expression and Its Clinical Significance in Circulating Tumor Cells from Patients with Non-Small-Cell Lung Cancer[J]. Cancer Manag Res, 2020, 12: 2069-2078. doi: 10.2147/CMAR.S245425
[27]	Dall'Olio FG, Gelsomino F, Conci N, et al. PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non-small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors[J]. Clin Lung Cancer, 2021, 22(5): 423-431. doi: 10.1016/j.cllc.2021.03.005
[28]	Bergmann S, Coym A, Ott L, et al. Evaluation of PD-L1 expression on circulating tumor cells (CTCs) in patients with advanced urothelial carcinoma (UC)[J]. Oncoimmunology, 2020, 9(1): 1738798. doi: 10.1080/2162402X.2020.1738798
[29]	Winograd P, Hou S, Court CM, et al. Hepatocellular Carcinoma-Circulating Tumor Cells Expressing PD-L1 Are Prognostic and Potentially Associated With Response to Checkpoint Inhibitors[J]. Hepatol Commun, 2020, 4(10): 1527-1540. doi: 10.1002/hep4.1577
[30]	Liu M, Wang R, Sun X, et al. Prognostic significance of PD-L1 expression on cell-surface vimentin-positive circulating tumor cells in gastric cancer patients[J]. Mol Oncol, 2020, 14(4): 865-881. doi: 10.1002/1878-0261.12643
[31]	Dong J, Zhu D, Tang X, et al. Circulating tumor cells in pulmonary vein and peripheral arterial provide a metric for PD-L1 diagnosis and prognosis of patients with non-small cell lung cancer[J]. PLoS One, 2019, 14(7): e0220306. doi: 10.1371/journal.pone.0220306
[32]	Zhang T, Agarwal A, Almquist RG, et al. Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer[J]. Biomark Res, 2021, 9(1): 14. doi: 10.1186/s40364-021-00267-y
[33]	Dhar M, Wong J, Che J, et al. Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer[J]. Sci Rep, 2018, 8(1): 2592. doi: 10.1038/s41598-018-19245-w
[34]	Rzhevskiy A, Kapitannikova A, Malinina P, et al. Emerging role of circulating tumor cells in immunotherapy[J]. Theranostics, 2021, 11(16): 8057-8075. doi: 10.7150/thno.59677
[35]	Wang Y, Yang X, Jia Z, et al. Clinical utility of PD-L1 expression in circulating tumor cells in non-small cell lung cancer patients treated with immunotherapy[J]. Chin J Clin Thorac Cardiovasc Surg, 2021, 28(1): 110-115.
[36]	Nakamura Y, Taniguchi H, Ikeda M, et al. Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies[J]. Nat Med, 2020, 26(12): 1859-1864. doi: 10.1038/s41591-020-1063-5
[37]	Chronopoulos A, Kalluri R. Emerging role of bacterial extracellular vesicles in cancer[J]. Oncogene, 2020, 39(46): 6951-6960. doi: 10.1038/s41388-020-01509-3

Cited By

Cited by

Periodical cited type(1)

周宁，王虎明，张萱，李丽莉，徐杰，高玉骞. D-二聚体与淋巴细胞比值对B细胞淋巴瘤患者预后预测的临床价值研究. 标记免疫分析与临床. 2023(10): 1688-1694 .

Other cited types(0)

Figures(1)

Get Citation

PDF

XML

Article views (2051) PDF downloads (805) Cited by(1)

Turn off MathJax

Article Contents

Abstract

References

Research Progress of PD-L1 Expression in Circulating Tumor Cells in Malignant Tumors